User menu

The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.

Bibliographic reference Cavalier, E ; Bergmann, P ; Bruyère, O ; Delanaye, P ; Durnez, A ; et. al. The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.. In: Osteoporosis International : with other metabolic bone diseases, Vol. 27, no.7, p. 2181-2195 (2016)
Permanent URL http://hdl.handle.net/2078.1/182998
  1. Kanis J. A., , McCloskey E. V., Johansson H., Cooper C., Rizzoli R., Reginster J.-Y., European guidance for the diagnosis and management of osteoporosis in postmenopausal women, 10.1007/s00198-012-2074-y
  2. Rizzoli R., Branco J., Brandi M.-L., Boonen S., Bruyère O., Cacoub P., Cooper C., Diez-Perez A., Duder J., Fielding R. A., Harvey N. C., Hiligsmann M., Kanis J. A., Petermans J., Ringe J. D., Tsouderos Y., Weinman J., Reginster J.-Y., Management of osteoporosis of the oldest old, 10.1007/s00198-014-2755-9
  3. Vasikaran S., , Eastell R., Bruyère O., Foldes A. J., Garnero P., Griesmacher A., McClung M., Morris H. A., Silverman S., Trenti T., Wahl D. A., Cooper C., Kanis J. A., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards, 10.1007/s00198-010-1501-1
  4. Bruyère Olivier, Reginster Jean-Yves, Monitoring of osteoporosis therapy, 10.1016/j.beem.2014.07.001
  5. Garnero Patrick, New developments in biological markers of bone metabolism in osteoporosis, 10.1016/j.bone.2014.05.016
  6. Halleen Jussi M., Alatalo Sari L., Suominen Harri, Cheng Sulin, Janckila Anthony J., Väänänen H. Kalervo, Tartrate-Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone Resorption, 10.1359/jbmr.2000.15.7.1337
  7. Garnero Patrick, Borel Olivier, Byrjalsen Inger, Ferreras Mercedes, Drake Fred H., McQueney Michael S., Foged Niels T., Delmas Pierre D., Delaissé Jean-Marie, The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases, 10.1074/jbc.273.48.32347
  8. Lotinun Sutada, Kiviranta Riku, Matsubara Takuma, Alzate Jorge A., Neff Lynn, Lüth Anja, Koskivirta Ilpo, Kleuser Burkhard, Vacher Jean, Vuorio Eero, Horne William C., Baron Roland, Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation, 10.1172/jci64840
  9. van Bezooijen Rutger L., Roelen Bernard A.J., Visser Annemieke, van der Wee-Pals Lianne, de Wilt Edwin, Karperien Marcel, Hamersma Herman, Papapoulos Socrates E., ten Dijke Peter, Löwik Clemens W.G.M., Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist, 10.1084/jem.20031454
  10. Papapoulos S. E., Targeting sclerostin as potential treatment of osteoporosis, 10.1136/ard.2010.141150
  11. Joiner Danese M., Ke Jiyuan, Zhong Zhendong, Xu H. Eric, Williams Bart O., LRP5 and LRP6 in development and disease, 10.1016/j.tem.2012.10.003
  12. Brunkow Mary E., Gardner Jessica C., Van Ness Jeff, Paeper Bryan W., Kovacevich Brian R., Proll Sean, Skonier John E., Zhao L., Sabo P.J., Fu Ying-Hui, Alisch Reid S., Gillett Lucille, Colbert Trenton, Tacconi Paolo, Galas David, Hamersma Herman, Beighton Peter, Mulligan John T., Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein, 10.1086/318811
  13. Ardawi M.-S. M., Al-Sibiany A. M., Bakhsh T. M., Rouzi A. A., Qari M. H., Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study, 10.1007/s00198-011-1806-8
  14. Garnero P., Sornay-Rendu E., Munoz F., Borel O., Chapurlat R. D., Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study, 10.1007/s00198-012-1978-x
  15. Durosier Claire, van Lierop Antoon, Ferrari Serge, Chevalley Thierry, Papapoulos Socrates, Rizzoli René, Association of Circulating Sclerostin With Bone Mineral Mass, Microstructure, and Turnover Biochemical Markers in Healthy Elderly Men and Women, 10.1210/jc.2013-2113
  16. Pelletier S., Dubourg L., Carlier M.-C., Hadj-Aissa A., Fouque D., The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD, 10.2215/cjn.07670712
  17. Biver Emmanuel, Chopin Florence, Coiffier Guillaume, Brentano Thomas Funck, Bouvard Béatrice, Garnero Patrick, Cortet Bernard, Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis, 10.1016/j.jbspin.2011.05.003
  18. Rogers A., Hannon R. A., Eastell R., Biochemical Markers as Predictors of Rates of Bone Loss After Menopause, 10.1359/jbmr.2000.15.7.1398
  19. Garnero Patrick, Cloos Paul, Sornay-Rendu E., Qvist Per, Delmas Pierre D., Type I Collagen Racemization and Isomerization and the Risk of Fracture in Postmenopausal Women: The OFELY Prospective Study, 10.1359/jbmr.2002.17.5.826
  20. Schousboe J. T., Bauer D. C., Nyman J. A., Kane R. L., Melton L. J., Ensrud K. E., Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy, 10.1007/s00198-006-0218-7
  21. Szulc Pawel, The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis, 10.1016/j.clinbiochem.2012.01.022
  22. Glover Sarah J., Eastell Richard, McCloskey Eugene V., Rogers Angela, Garnero Patrick, Lowery Jonathan, Belleli Rossella, Wright Timothy M., John Markus R., Rapid and robust response of biochemical markers of bone formation to teriparatide therapy, 10.1016/j.bone.2009.07.091
  23. Jilka Robert L., Molecular and cellular mechanisms of the anabolic effect of intermittent PTH, 10.1016/j.bone.2007.03.017
  24. Eastell Richard, Krege John H., Chen Peiqi, Glass Emmett V., Reginster Jean-Yves, Development of an algorithm for using PINP to monitor treatment of patients with teriparatide, 10.1185/030079905x75096
  25. Hwang J. S., Chen J. F., Yang T. S., Wu D. J., Tsai K. S., Ho C., Wu C. H., Su S. L., Wang C. J., Tu S. T., The Effects of Strontium Ranelate in Asian Women with Postmenopausal Osteoporosis, 10.1007/s00223-009-9233-y
  26. Blumsohn A., , Marin F., Nickelsen T., Brixen K., Sigurdsson G., González de la Vera J., Boonen S., Liu-Léage S., Barker C., Eastell R., Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide, 10.1007/s00198-010-1379-y
  27. Delmas Pierre D., Vrijens Bernard, Eastell Richard, Roux Christian, Pols Huibert A. P., Ringe Johann D., Grauer Andreas, Cahall David, Watts Nelson B., Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis, 10.1210/jc.2006-1526
  28. Baim Sanford, Miller Paul D, Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw, 10.1359/jbmr.090203
  29. Goemaere S, Van Pottelbergh I, Zmierczak H, Toye K, Daems M, Demuynck R, Myny H, De Bacquer D, Kaufman J.M, Inverse association between bone turnover rate and bone mineral density in community-dwelling men >70 years of age: no major role of sex steroid status, 10.1016/s8756-3282(01)00503-8
  30. Darelid Anna, Nilsson Martin, Kindblom Jenny M., Mellström Dan, Ohlsson Claes, Lorentzon Mattias, Bone Turnover Markers Predict Bone Mass Development in Young Adult Men: A Five-Year Longitudinal Study, 10.1210/jc.2014-3947
  31. Dennison E., Eastell R., Fall C. H. D., Kellingray S., Wood P. J., Cooper C., Determinants of Bone Loss in Elderly Men and Women: A Prospective Population-Based Study, 10.1007/s001980050244
  32. Stoch S. Aubrey, Parker Robert A., Chen Liping, Bubley Glenn, Ko Yoo-Joung, Vincelette Aimee, Greenspan Susan L., Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists1, 10.1210/jcem.86.6.7558
  33. Szulc P, Montella A, Delmas P D, High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study, 10.1136/ard.2007.077941
  34. Bauer Douglas C, Garnero Patrick, Harrison Stephanie L, Cauley Jane A, Eastell Richard, Ensrud Kris E, Orwoll Eric, Biochemical Markers of Bone Turnover, Hip Bone Loss, and Fracture in Older Men: The MrOS Study, 10.1359/jbmr.090526
  35. Meier Christian, Nguyen Tuan V, Center Jacqueline R, Seibel Markus J, Eisman John A, Bone Resorption and Osteoporotic Fractures in Elderly Men: The Dubbo Osteoporosis Epidemiology Study, 10.1359/jbmr.041207
  36. Luukinen H., Käkönen S.-M., Pettersson K., Koski K., Laippala P., Lövgren T., Kivelä S.-L., Väänänen H. K., Strong Prediction of Fractures Among Older Adults by the Ratio of Carboxylated to Total Serum Osteocalcin, 10.1359/jbmr.2000.15.12.2473
  37. Kaufman Jean-Marc, Lapauw Bruno, Goemaere Stefan, Current and future treatments of osteoporosis in men, 10.1016/j.beem.2014.09.002
  38. Orwoll Eric, Teglbjærg Christence S., Langdahl Bente L., Chapurlat Roland, Czerwinski Edward, Kendler David L., Reginster Jean-Yves, Kivitz Alan, Lewiecki E. Michael, Miller Paul D., Bolognese Michael A., McClung Michael R., Bone Henry G., Ljunggren Östen, Abrahamsen Bo, Gruntmanis Ugis, Yang Yu-Ching, Wagman Rachel B., Siddhanti Suresh, Grauer Andreas, Hall Jesse W., Boonen Steven, A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density, 10.1210/jc.2012-1569
  39. Magee Laura A., von Dadelszen Peter, Rey Evelyne, Ross Susan, Asztalos Elizabeth, Murphy Kellie E., Menzies Jennifer, Sanchez Johanna, Singer Joel, Gafni Amiram, Gruslin Andrée, Helewa Michael, Hutton Eileen, Lee Shoo K., Lee Terry, Logan Alexander G., Ganzevoort Wessel, Welch Ross, Thornton Jim G., Moutquin Jean-Marie, Less-Tight versus Tight Control of Hypertension in Pregnancy, 10.1056/nejmoa1404595
  40. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman J-M, Clancy AD, Gaich GA, The Effect of Teriparatide [Human Parathyroid Hormone (1-34)] Therapy on Bone Density in Men With Osteoporosis, 10.1359/jbmr.2003.18.1.9
  41. Farahmand P., Marin F., Hawkins F., Möricke R., Ringe J. D., Glüer C.-C., Papaioannou N., Minisola S., Martínez G., Nolla J. M., Niedhart C., Guañabens N., Nuti R., Martín-Mola E., Thomasius F., Peña J., Graeff C., Kapetanos G., Petto H., Gentzel A., Reisinger A., Zysset P. K., Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis, 10.1007/s00198-013-2379-5
  42. Seibel MJ (2005) Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26:97–122
  43. Naylor Kim, Eastell Richard, Bone turnover markers: use in osteoporosis, 10.1038/nrrheum.2012.86
  44. Ivaska Kaisa K., Lenora Janaka, Gerdhem Paul, Åkesson Kristina, Väänänen H. Kalervo, Obrant Karl J., Serial Assessment of Serum Bone Metabolism Markers Identifies Women with the Highest Rate of Bone Loss and Osteoporosis Risk, 10.1210/jc.2007-1508
  45. Khosla S., Relationship of Serum Sex Steroid Levels and Bone Turnover Markers with Bone Mineral Density in Men and Women: A Key Role for Bioavailable Estrogen, 10.1210/jc.83.7.2266
  46. Garnero Patrick, Sornay-Rendu Elisabeth, Duboeuf François, Delmas Pierre D., Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study, 10.1359/jbmr.1999.14.9.1614
  47. Szulc Pawel, Biochemical Bone Turnover Markers and Osteoporosis in Older Men: Where Are We?, 10.4061/2011/704015
  48. Johansson Helena, , Odén Anders, Kanis John A., McCloskey Eugene V., Morris Howard A., Cooper Cyrus, Vasikaran Samuel, A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture, 10.1007/s00223-014-9842-y
  49. Gielen E., O’Neill T., Pye S., Adams J., Ward K., Wu F., Laurent M., Claessens F., Boonen S., Vanderschueren D., Verschueren S., Bone turnover markers predict hip bone loss in elderly European men: results of the European Male Ageing Study (EMAS), 10.1007/s00198-014-2884-1
  50. Devogelaer Jean-Pierre, Glucocorticoid-Induced Osteoporosis: Mechanisms and Therapeutic Approach, 10.1016/j.rdc.2006.09.001
  51. Weinstein R S, Jilka R L, Parfitt A M, Manolagas S C, Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone., 10.1172/jci2799
  52. Paglia F, Dionisi S, De Geronimo S et al (2001) Biomarkers of bone turnover after a short period of steroid therapy in elderly men. Clin Chem 47:1314–6
  53. Szappanos Á., Tőke J., Lippai D., Patócs A., Igaz P., Szücs N., Fütő L., Gláz E., Rácz K., Tóth M., Bone turnover in patients with endogenous Cushing’s syndrome before and after successful treatment, 10.1007/s00198-009-0978-y
  54. Kaji H., Kuroki Y., Murakawa Y., Funakawa I., Funasaka Y., Kanda F., Sugimoto T., Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study, 10.1007/s00198-009-1110-z
  55. von Tirpitz C, Epp S, Klaus J et al (2003) Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn’s disease. Eur J Gastroenterol Hepatol 15:1165–1170. doi: 10.1097/01.meg.0000085485.12407.82
  56. Fahrleitner A, Prenner G, Leb G, Tscheliessnigg K.H, Piswanger-Sölkner C, Obermayer-Pietsch B, Portugaller H.R, Berghold A, Dobnig H, Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation, 10.1016/s8756-3282(02)00926-2
  57. Devogelaer J.-P., Sambrook P., Reid D. M., Goemaere S., Ish-Shalom S., Collette J., Su G., Bucci-Rechtweg C., Papanastasiou P., Reginster J.-Y., Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids, 10.1093/rheumatology/kes410
  58. Saag Kenneth G., Zanchetta Jose R., Devogelaer Jean-Pierre, Adler Robert A., Eastell Richard, See Kyoungah, Krege John H., Krohn Kelly, Warner Margaret R., Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial : Teriparatide Versus Alendronate in Glucocorticoid-Induced OP, 10.1002/art.24879
  59. Coleman R., Body J. J., Aapro M., Hadji P., Herrstedt J., , Bone health in cancer patients: ESMO Clinical Practice Guidelines, 10.1093/annonc/mdu103
  60. Ferreira Arlindo, Alho Irina, Casimiro Sandra, Costa Luís, Bone remodeling markers and bone metastases: From cancer research to clinical implications, 10.1038/bonekey.2015.35
  61. Coleman Robert, Costa Luis, Saad Fred, Cook Richard, Hadji Peyman, Terpos Evangelos, Garnero Patrick, Brown Janet, Body Jean-Jacques, Smith Matthew, Lee Ker-Ai, Major Pierre, Dimopoulos Meletios, Lipton Allan, Consensus on the utility of bone markers in the malignant bone disease setting, 10.1016/j.critrevonc.2011.02.005
  62. Costa L., Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status, 10.1200/jco.20.3.850
  63. Som A, Tu S-M, Liu J, Wang X, Qiao W, Logothetis C, Corn P G, Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials, 10.1038/bjc.2012.436
  64. Abildgaard N, Brixen K, Eriksen EF et al (2004) Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 89:567–577
  65. Coleman Robert E., Major Pierre, Lipton Allan, Brown Janet E., Lee Ker-Ai, Smith Matthew, Saad Fred, Zheng Ming, Hei Yong Jiang, Seaman John, Cook Richard, Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid, 10.1200/jco.2005.06.091
  66. Body Jean-Jacques, Denosumab for the management of bone disease in patients with solid tumors, 10.1586/era.11.204
  67. Brown J. E., Cook R. J., Major P., Lipton A., Saad F., Smith M., Lee K.-A., Zheng M., Hei Y.-J., Coleman R. E., Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors, 10.1093/jnci/dji002
  68. Delanaye P., Souberbielle J.-C., Lafage-Proust M.-H., Jean G., Cavalier E., Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts, 10.1093/ndt/gft275
  69. Torres Pablo Ureña, Bover Jordi, Mazzaferro Sandro, de Vernejoul Marie Christine, Cohen-Solal Martine, When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease, 10.1016/j.semnephrol.2014.09.004
  70. Eckardt Kai-Uwe, Kasiske Bertram L, Foreword, 10.1038/ki.2009.188
  71. Cavalier E., Delanaye P., Vranken L., Bekaert A.-C., Carlisi A., Chapelle J.-P., Souberbielle J.-C., Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values, 10.1093/ndt/gfr535
  72. Chu Pauling, Chao Tsu-Yi, Lin Yuh-Feng, Janckila Anthony J, Yam Lung T, Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis, 10.1016/s0272-6386(03)00203-8
  73. Moorthi RN, Moe SM (2014) Recent advances in the noninvasive diagnosis of renal osteodystrophy. Kidney Int 84:886–894. doi: 10.1038/ki.2013.254.Recent
  74. Malluche H. H., Davenport D. L., Cantor T., Monier-Faugere M.-C., Bone Mineral Density and Serum Biochemical Predictors of Bone Loss in Patients with CKD on Dialysis, 10.2215/cjn.09470913
  75. Sanz-Salvador L., Garcia-Perez M. A., Tarin J. J., Cano A., ENDOCRINOLOGY IN PREGNANCY: Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture, 10.1530/eje-14-0424
  76. Honjo Shigeichiro, Mizunuma Hideki, Changes in biochemical parameters of bone turnover and bone mineral density in post-pregnancy osteoporosis, 10.1067/mob.2001.113910
  77. Orford N., Cattigan C., Brennan S. L., Kotowicz M., Pasco J., Cooper D. J., The association between critical illness and changes in bone turnover in adults: a systematic review, 10.1007/s00198-014-2734-1
  78. Rousseau Anne-Françoise, Damas Pierre, Janssens Marc, Kalin Saban, Ledoux Didier, Le Goff Caroline, Gadisseur Romy, Delanaye Pierre, Cavalier Etienne, Critical care and vitamin D status assessment: What about immunoassays and calculated free 25OH-D?, 10.1016/j.cca.2014.07.007
  79. Orford Neil R., Saunders Kym, Merriman Elizabeth, Henry Margaret, Pasco Julie, Stow Peter, Kotowicz Mark, Skeletal morbidity among survivors of critical illness* : , 10.1097/ccm.0b013e318211ff3d
  80. Klein Gordon L., Xie Yixia, Qin Yi-Xian, Lin Liangjun, Hu Minyi, Enkhbaatar Perenlei, Bonewald Lynda F., Preliminary evidence of early bone resorption in a sheep model of acute burn injury: an observational study, 10.1007/s00774-013-0483-4
  81. Klein Gordon L., Herndon David N., Rutan Thomas C., Sherrard Donald J., Coburn Jack W., Langman Craig B., Thomas Mary L., Haddad John G., Cooper Cary W., Miller Nancy L., Alfrey Allen C., Bone disease in burn patients, 10.1002/jbmr.5650080311
  82. Terzi Rabia, Güven Murat, Bone Mineral Density After Burn Injury and Its Relation to the Characteristics of Scar Tissue : , 10.1097/bcr.0000000000000241
  83. Klein Gordon L., Herndon David N., Langman Craig B., Rutan Thomas C., Young William E., Pembleton Gregory, Nusynowitz Martin, Barnett Joseph L., Broemeling Lyle D., Sailer Dawn E., McCauley Robert L., Long-term reduction in bone mass after severe burn injury in children, 10.1016/s0022-3476(95)70553-8
  84. Nierman David M., Mechanick Jeffrey I., Biochemical Response to Treatment of Bone Hyperresorption in Chronically Critically Ill Patients, 10.1378/chest.118.3.761
  85. Klein Gordon L., Wimalawansa Sunil J., Kulkarni Gayathri, Sherrard Donald J., Sanford Arthur P., Herndon David N., The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study, 10.1007/s00198-004-1731-1
  86. Przkora Rene, Herndon David N., Sherrard Donald J., Chinkes David L., Klein Gordon L., Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury, 10.1016/j.bone.2007.04.195
  87. Porro LJ et al (2012) Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy. J Am Coll Surg 214:489–504. doi: 10.1016/j.biotechadv.2011.08.021.Secreted
  88. Przkora Rene, Herndon David N., Suman Oscar E., Jeschke Marc G., Meyer Walter J., Chinkes David L., Mlcak Ronald P., Huang Ted, Barrow Robert E., Beneficial Effects of Extended Growth Hormone Treatment After Hospital Discharge in Pediatric Burn Patients : , 10.1097/01.sla.0000219676.69331.fd
  89. Khan Tayyab S., Fraser Lisa-Ann, Type 1 Diabetes and Osteoporosis: From Molecular Pathways to Bone Phenotype, 10.1155/2015/174186
  90. Dede Anastasia D., Tournis Symeon, Dontas Ismene, Trovas George, Type 2 diabetes mellitus and fracture risk, 10.1016/j.metabol.2014.09.002
  91. Gilbert Matthew P., Pratley Richard E., The Impact of Diabetes and Diabetes Medications on Bone Health, 10.1210/er.2012-1042
  92. Farr Joshua N., Khosla Sundeep, Determinants of bone strength and quality in diabetes mellitus in humans, 10.1016/j.bone.2015.07.027
  93. Ferrari Serge, Future directions for new medical entities in osteoporosis, 10.1016/j.beem.2014.08.002
  94. Bone Henry G, McClung Michael R, Roux Christian, Recker Robert R, Eisman John A, Verbruggen Nadia, Hustad Carolyn M, DaSilva Carolyn, Santora Arthur C, Ince B Avery, Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density, 10.1359/jbmr.091035
  95. Borel Olivier, Gineyts Evelyne, Bertholon Cindy, Garnero Patrick, Cathepsin K Preferentially Solubilizes Matured Bone Matrix, 10.1007/s00223-012-9604-7
  96. Pennypacker Brenda L, Chen Charles M, Zheng Helen, Shih Mei-Shu, Belfast Mary, Samadfam Rana, Duong Le T, Inhibition of Cathepsin K Increases Modeling-Based Bone Formation, and Improves Cortical Dimension and Strength in Adult Ovariectomized Monkeys : ODANACATIB STIMULATES CORTICAL BONE FORMATION IN OVARIECTOMIZED MONKEYS, 10.1002/jbmr.2211
  97. McClung Michael R., Grauer Andreas, Boonen Steven, Bolognese Michael A., Brown Jacques P., Diez-Perez Adolfo, Langdahl Bente L., Reginster Jean-Yves, Zanchetta Jose R., Wasserman Scott M., Katz Leonid, Maddox Judy, Yang Yu-Ching, Libanati Cesar, Bone Henry G., Romosozumab in Postmenopausal Women with Low Bone Mineral Density, 10.1056/nejmoa1305224
  98. Ominsky Michael S, Niu Qing-Tian, Li Chaoyang, Li Xiaodong, Ke Hua Zhu, Tissue-Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody : SCLEROSTIN ANTIBODY TISSUE-LEVEL EFFECTS, 10.1002/jbmr.2152
  99. Nioi Paul, Taylor Scott, Hu Rong, Pacheco Efrain, He Yudong D, Hamadeh Hisham, Paszty Chris, Pyrah Ian, Ominsky Michael S, Boyce Rogely Waite, Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats : TRANSCRIPTIONAL PROFILING OF OSTEOBLAST LINEAGE AND EARLY RESPONSE TO SCL-AB, 10.1002/jbmr.2482
  100. Leder Benjamin Z., O'Dea Louis St.L., Zanchetta José R., Kumar Prasana, Banks Kathleen, McKay Kathleen, Lyttle C. Richard, Hattersley Gary, Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis, 10.1210/jc.2014-3718